Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
Necrosis01:16

Necrosis

4.4K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bone marrow edema as an independent imaging predictor of dedifferentiated chondrosarcoma.

Journal of orthopaedic surgery and research·2026
Same author

Local Recurrence and Metastasis Define Distinct Recurrence Phenotypes in Soft Tissue Sarcoma.

Cancers·2026
Same author

Lower Eyelid Fat Pad Transfer and Upper Eyelid Blepharoplasty for Simultaneous Correction of Tear Trough and Sunken Upper Eyelid Deformities.

Aesthetic plastic surgery·2026
Same author

Spatiotemporal Heterogeneity and the Impact of PM1 and Nitrogen Oxides on Chronic Kidney Disease Mortality in 39 European Countries (1990-2022): A Multi-Model Analysis.

International journal of nephrology and renovascular disease·2026
Same author

Heat stress exposure and incidence of chronic kidney disease.

iScience·2026
Same author

Inflammatory biomarker-based prognostic model for immunotherapy outcomes in patients with recurrent or metastatic cervical cancer.

Frontiers in oncology·2026

Related Experiment Video

Updated: Jun 16, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.5K

Rethinking the Prognostic Role of Necrosis in Soft-Tissue Sarcoma: Multidisciplinary Insights from the Sarcoma

Beata Bode-Lesniewska1, Hans Roland Dürr2, Dian Wang3

  • 1Institute for Pathology, LUKS University Hospital, Spitalstrasse 1, 6000 Luzern, Switzerland.

Cancers
|June 13, 2025
PubMed
Summary

Therapy-induced necrosis in soft-tissue sarcomas (STSs) is not a reliable predictor of outcomes. A multidisciplinary approach focusing on viable tumor cells and advanced methods is crucial for personalized STS management.

Keywords:
hybrid trial designneoadjuvant therapypersonalized medicineprognostic markerradiomicsreal-world evidencesoft-tissue sarcomatumor necrosis

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.3K
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.4K

Related Experiment Videos

Last Updated: Jun 16, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.5K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.3K
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.4K

Area of Science:

  • Oncology
  • Pathology
  • Radiology

Background:

  • Soft-tissue sarcomas (STSs) are diverse cancers with variable treatment responses.
  • The prognostic value of therapy-induced necrosis in STSs is uncertain due to inconsistent definitions and methodologies.
  • Spontaneous necrosis is recognized, but post-treatment necrosis interpretation is complicated by clinical confounders.

Purpose of the Study:

  • To critically assess the utility of therapy-induced necrosis in managing soft-tissue sarcomas.
  • To synthesize multidisciplinary perspectives on defining, measuring, and contextualizing necrosis in STS patient care.
  • To explore standardized and emerging approaches for evaluating treatment response in STSs.

Main Methods:

  • International, multidisciplinary webinar hosted by the Sarcoma Academy.
  • Discussions included surgical, pathological, oncological, and radiological viewpoints.
  • Critical assessment of necrosis definition, measurement, and clinical relevance in STS.

Main Results:

  • STS heterogeneity and varied treatments challenge the prognostic value of post-treatment necrosis.
  • Substantial necrosis can indicate effective therapy or aggressive tumor biology.
  • Measuring viable tumor cells offers a more standardized measure of therapy response.
  • Radiomics, molecular profiling, and RWE protocols show promise for personalized STS therapy.

Conclusions:

  • Solely focusing on therapy-induced necrosis is insufficient for predicting STS outcomes.
  • A multidisciplinary framework with standardized pathology, viable cell quantification, and advanced imaging is needed.
  • Future studies should identify STS subgroups benefiting from intensified necrosis-focused treatments and balance them with clinical factors.